{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Auto-injector+%28AI%29",
    "query": {
      "intervention": "Auto-injector (AI)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Auto-injector+%28AI%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T03:04:50.934Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03707717",
      "title": "A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma S.P.R.L.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 189,
      "start_date": "2018-10-15",
      "completion_date": "2019-06-05",
      "has_results": false,
      "last_update_posted_date": "2020-06-16",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03707717"
    },
    {
      "nct_id": "NCT02675023",
      "title": "Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "M923",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Momenta Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 603,
      "start_date": "2016-01",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2019-10-15",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675023"
    },
    {
      "nct_id": "NCT06293365",
      "title": "Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sjögrens Disease",
        "Systemic Lupus Erythematosus",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "VAY736 1ml PFS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAY736 2 ml PFS",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VAY736 2ml AI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 155,
      "start_date": "2024-07-02",
      "completion_date": "2029-01-16",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 17,
      "location_summary": "Anniston, Alabama • Fullerton, California • La Palma, California + 14 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06293365"
    },
    {
      "nct_id": "NCT03766685",
      "title": "A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Psoriasis",
        "Moderate to Severe Chronic Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2018-12-20",
      "completion_date": "2020-09-08",
      "has_results": true,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • San Diego, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Luis Obispo",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03766685"
    },
    {
      "nct_id": "NCT02996019",
      "title": "A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Etrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Auto-Injector (AI)",
          "type": "DEVICE"
        },
        {
          "name": "Prefilled Syringe With Needle Safety Device (PFS-NSD)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 180,
      "start_date": "2016-12-07",
      "completion_date": "2018-04-09",
      "has_results": false,
      "last_update_posted_date": "2018-12-03",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 4,
      "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02996019"
    },
    {
      "nct_id": "NCT04333147",
      "title": "Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis, Rheumatoid"
      ],
      "interventions": [
        {
          "name": "Otilimab (GSK3196165)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "csDMARD(s)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2916,
      "start_date": "2020-05-12",
      "completion_date": "2023-02-24",
      "has_results": true,
      "last_update_posted_date": "2024-02-07",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 79,
      "location_summary": "Anniston, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 63 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04333147"
    },
    {
      "nct_id": "NCT03415178",
      "title": "Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab SAR236553",
          "type": "DRUG"
        },
        {
          "name": "Current auto-injector device (AI)",
          "type": "DEVICE"
        },
        {
          "name": "New auto-injector device (SYDNEY)",
          "type": "DEVICE"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2018-03-29",
      "completion_date": "2018-08-09",
      "has_results": true,
      "last_update_posted_date": "2019-09-09",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Jacksonville, Florida • Ponte Vedra, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Ponte Vedra",
          "state": "Florida"
        },
        {
          "city": "Wellington",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03415178"
    },
    {
      "nct_id": "NCT03662100",
      "title": "A Study of Two Formulations of LY3074828 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3074828",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LY3074828",
          "type": "DRUG"
        },
        {
          "name": "Auto-injector (AI)",
          "type": "DEVICE"
        },
        {
          "name": "Prefilled syringe (PFS)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2018-09-06",
      "completion_date": "2019-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03662100"
    },
    {
      "nct_id": "NCT05405985",
      "title": "Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Nemolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 192,
      "start_date": "2022-08-11",
      "completion_date": "2022-12-08",
      "has_results": true,
      "last_update_posted_date": "2025-01-03",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 2,
      "location_summary": "Tempe, Arizona • Lincoln, Nebraska",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05405985"
    },
    {
      "nct_id": "NCT03491904",
      "title": "To Assess the Patients' Ability to Self-Administer Fasinumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteoarthritis, Knee",
        "Osteoarthritis, Hip"
      ],
      "interventions": [
        {
          "name": "Fasinumab AI",
          "type": "DRUG"
        },
        {
          "name": "Fasinumab PFS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-01-23",
      "completion_date": "2020-12-15",
      "has_results": false,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-09-09T03:04:50.934Z",
      "location_count": 23,
      "location_summary": "Gilbert, Arizona • Glendale, Arizona • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03491904"
    }
  ]
}